There is more to the Danish major than diabetes and Ludovic Helfgott gave In Vivo an insight to the firm’s ambitious plans for its renamed rare diseases division.
Novo Nordisk A/S may be best known for its diabetes and obesity businesses, but the Danish group is determined to make its presence more keenly felt in the rare diseases space; an area in which it has been active for over four decades.
The Copenhagen-headquartered group announced at a recent capital markets day that it has changed the name of its biopharm franchise to Novo Nordisk Rare Disease. The new division is headed...
Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.
From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.
Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.
